Abstract
INTRODUCTION: Rosacea, a chronic skin disease characterized by facial redness, is believed to involve inflammation and angiogenesis in its pathogenesis. Endocan and endoglin, biomarkers associated with vascular and inflammatory processes, might play roles in rosacea and cardiovascular comorbidities. OBJECTIVES: This study aimed to assess serum levels of endocan and endoglin in individuals with rosacea and the function of these biomarkers in indicating comorbidities associated with rosacea. METHODS: A total of forty-four patients diagnosed with rosacea and thirty-three healthy controls were included in this case-control study. The endocan and endoglin levels in serum samples from both groups were measured. RESULTS: No significant difference in endocan and endoglin levels was observed between the patient and control groups. However, their levels were associated with various clinical features, including symptom and disease severity. A notable association was identified between waist circumference, body mass index, and endoglin levels. However, this association was not evident for endocan. CONCLUSIONS: This study suggests endocan and endoglin may play roles in rosacea pathogenesis, with endoglin potentially associated with increased cardiovascular risk.